Exphar SA
27.0 FTEThe score of Exphar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +9 % Equity -15 % Total assets -15 % Headcount (avg FTE) +74 %
Accounts of the company itself (not consolidated).
The full file covers 11 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Exphar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €22.9m | ||||
| Net result | 868,458 € | ||||
| Equity | €5.54m | ||||
| Cash | €1.75m | ||||
| EBITDA | €2.06m | ||||
| Total assets | €14.1m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 14 Jul 2026
- Year ended 31 Dec 2024filed on 04 Aug 2025
- Year ended 31 Dec 2023filed on 25 Jun 2024
- Year ended 31 Dec 2022filed on 18 Jul 2023
- Year ended 31 Dec 2021filed on 13 Jul 2022
Exphar's financial analysis
- Solvency39.2%sector median: 43.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Exphar
Exphar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0421.802.718
- VAT number
- BE0421802718
- Peppol
- Registered · 0208:0421802718 · as of 09 Nov 2026
- Legal form
- SA
- Incorporated
- 27 Aug 1981
- Registered office
- 1402 Nivelles
- Size
- Small · 27.0 FTE
- Latest accounts
- 2025 · filed on 14 Jul 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Exphar (SA) has been based in Nivelles since 1981, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports revenue of €22.9m, a net profit of 868,458 € and equity of €5.54m. With 27.0 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 39.2%, below the median of its sector (43.9%).
Companies similar to Exphar
Companies in the same business, of comparable size and area, outside its group.
- Departement Central DE Fractionnement Manufacture of pharmaceutical preparations Brussels · balance sheet €19.7m
- Derco - Anciens Etablissements Jos. Derycke Wholesale of pharmaceutical and medical goods Ittre · balance sheet €3.71m
- Norgine Wholesale of pharmaceutical and medical goods Leuven · balance sheet €14.1m
- Antwerps Distributie Centrum Wholesale of pharmaceutical and medical goods Kontich · balance sheet €15.4m
- Euro - Medic Wholesale of pharmaceutical and medical goods Deinze · balance sheet €14.1m
- Thea Pharma Wholesale of pharmaceutical and medical goods Ghent · balance sheet €16.7m
- ixX pharma Wholesale of pharmaceutical and medical goods Antwerp · balance sheet €11.3m
- Zambon Wholesale of pharmaceutical and medical goods Jette · balance sheet €7.67m
Frequently asked questions about Exphar
What is the revenue of Exphar?
According to the 2025 annual accounts filed with the NBB, the revenue of Exphar amounts to 22,881,746 €.
What is the VAT number of Exphar?
In Belgium, the VAT number is the company number prefixed with BE: BE0421802718 for Exphar, if the company is VAT-registered. Its company number (CBE) is 0421.802.718.
Where is the registered office of Exphar?
According to the CBE register, the registered office of Exphar is in 1402 Nivelles.
What is the equity of Exphar?
At the close of the 2025 financial year, the equity of Exphar amounts to 5,541,340 €, a solvency of 39.2% of total assets.
How many people work at Exphar?
27.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Exphar?
The register lists 6 active mandates at Exphar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Exphar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →